Dashboard
Poor Management Efficiency with a low ROCE of 0.85%
- The company has been able to generate a Return on Capital Employed (avg) of 0.85% signifying low profitability per unit of total capital (equity and debt)
Poor long term growth as Operating profit has grown by an annual rate 8.14% of over the last 5 years
Flat results in Jun 25
With ROE of 5.08%, it has a attractive valuation with a 0.81 Price to Book Value
Reducing Promoter Confidence
Below par performance in long term as well as near term
Stock DNA
Computers - Software & Consulting
USD 887 Million (Micro Cap)
16.00
NA
0.00%
0.13
5.99%
0.89
Total Returns (Price + Dividend) 
Angi, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is Angi, Inc. overvalued or undervalued?
As of 28 November 2025, the valuation grade for Angi, Inc. has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 16, a Price to Book Value of 0.81, and an EV to EBITDA of 8.45, which suggests that the stock is trading at a premium compared to its earnings and book value. In comparison to peers, Angi, Inc. has a P/E ratio of 14.77, while GoodRx Holdings, Inc. stands out with a much higher P/E of 31.76, indicating a significant valuation disparity. Additionally, eGain Corp. shows a P/E of 6.67, further emphasizing Angi's expensive valuation relative to its peers. Although specific return data is not available, the lack of recent performance metrics against the S&P 500 reinforces the notion that Angi, Inc. may not be a compelling investment at its current valuation....
Read MoreIs Angi, Inc. overvalued or undervalued?
As of 28 November 2025, the valuation grade for Angi, Inc. has moved from fair to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its P/E ratio of 16, which is higher than the industry average, and an EV to EBITDA ratio of 8.45, which suggests a premium compared to peers. Additionally, the Price to Book Value stands at 0.81, reflecting a relatively low valuation against its book value. In comparison to its peers, Angi, Inc. has a P/E ratio of 14.77, while GoodRx Holdings, Inc. shows a much higher P/E of 31.76, indicating that Angi is not only overvalued but also less attractive than some competitors. The return comparison with the S&P 500 is not available, but the current valuation metrics reinforce the conclusion that Angi, Inc. is overvalued in the current market context....
Read MoreIs Angi, Inc. overvalued or undervalued?
As of 7 November 2025, the valuation grade for Angi, Inc. has moved from expensive to fair. Based on the current metrics, Angi appears to be fairly valued. Key ratios include a P/E ratio of 16, a Price to Book Value of 0.81, and an EV to EBITDA of 8.45. In comparison to peers, Angi's P/E ratio of 14.77 is more attractive than Sharecare, Inc. which is risky with a P/E of -5.08, and GoodRx Holdings, Inc. which is fair with a P/E of 31.76. While specific return data is not available, the overall valuation suggests that Angi, Inc. is positioned reasonably within its industry, especially when compared to its peers....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 24 Schemes (4.61%)
Held by 69 Foreign Institutions (2.59%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 13.14% vs -8.21% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is -27.81% vs 1,261.54% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -12.78% vs -22.99% in Dec 2023
YoY Growth in year ended Dec 2024 is 222.67% vs 66.37% in Dec 2023






